Use access key #2 to skip to page content.
$26.71 -1.80 (-6.31%)
8/20/2008 3:23 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
**

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

View All Commentary (AMLN)

Recs

2

Avatar TotoMMB (99.36) Submitted: 12/24/07 4:09 AM : Outperform Start Price: $38.00 AMLN Score: -15.95

Real hit or miss buy. Seems to be stuck between 35 and 50. Currently on the low end, I'd buy, only to ride the roller coaster. With only a couple products to it's name, it's going to hit big or miss big. While that may be a ways off, it may pop back up to near it's 200-day avg of mid-40s. Once in the 46-50 range, get out and wait for it to dip again. Short-term outperform as S&P advances little over the next 2-3 months.

Report this Post Replies: 0 | Reply

Featured Broker Partners